Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | PRF1 | P14222 | 1/20 | 0.31 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | GNRHR | P30968 | 1/20 | 0.30 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20137967 | 0.87 | MAPK1 (0.43) | BRD4SHMT2JAK2JAK1TYK2 | |
| SCHEMBL20137971 | 0.75 | SMN1; SMN2 (0.36) | GAATSHRBRD4SHMT2NPC1 | |
| SCHEMBL20137915 | 0.75 | MAPK1 (0.41) | BRD4 | |
| SCHEMBL20138147 | 0.74 | MAPK1 (0.44) | PRF1GNRHR | |
| SCHEMBL20138092 | 0.73 | SMN1; SMN2 (0.36) | SHMT2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20138109 | 0.73 | MAPK1 (0.43) | BRD4PRF1JAK2JAK1TYK2 | |
| SCHEMBL20138130 | 0.73 | MAPK1 (0.42) | — | |
| SCHEMBL20138189 | 0.72 | SMN1; SMN2 (0.34) | TSHRBRD4SHMT2NPC1RAB9A | |
| SCHEMBL20138244 | 0.72 | MAPK1 (0.41) | PRF1SHMT2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20138232 | 0.70 | MAPK1 (0.42) | PRF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | UCB BIOPHARMA SPRL (BE) | 2019-05-14 | — | — | US | disclosed |
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | UCB S.A. (BE) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | TNF, NFKBIA, TNFRSF1A | DRD2 1679/4885GAA 615/4885TSHR 2169/4885 |
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | TNF, TNFRSF1A, NFKBIA | DRD2 1711/4885GAA 1575/4885TSHR 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.